rheumatoid arthritis

Jan 14, 2025

Agios’ PYRUKYND SNDA Accepted by FDA for Thalassemia; BridgeBio’s BBO-8520 Gets FDA Fast Track for KRASG12C-Mutated Lung Cancer; Nipocalimab Granted FDA Priority Review for Myasthenia Gravis; Rigel’s R289 Receives FDA Orphan Drug Designation for MDS; Rise Therapeutics Gets FDA IND Clearance for R-5780 in Cancer

Nov 05, 2024

Prolong’s PP-007 Fast-Tracked for Stroke; FDA Expands JYLAMVO Pediatric Approval; Corcept’s Cushing’s Drug Shows Positive Phase III Results; ESSA Halts Phase II Study of Masofaniten for Prostate Cancer; SCEMBLIX Approved for Leukemia

Oct 04, 2024

Fierce Competition Lies Ahead for Pipeline Therapies in the Rheumatoid Arthritis Market

Oct 02, 2024

The Present Rheumatoid Arthritis Treatment Market Offers a Mix-and-Match Approach

Sep 06, 2024

Could Hidradenitis Suppurativa Be Another Psoriasis?

Oct 11, 2023

Harnessing the Power of Immunomodulators: Applications and Implications

Mar 16, 2022

Can Cannabinoids be an Effective Medicinal Substance?

Jan 25, 2022

Merck’s Gefapixant; Pfizer’s Somatrogon; Gilead’s Viklury; AbbVie’s Skyrizi; Gilead’s Zydelig Approvals; Lantern’s LP-184; Polpharma to Acquire Advent

Aug 20, 2020

FDA rejects BioMarin’s Valoctocogene Roxaparvovec; J&J inks $6.5B deal; Alzheon bags $47M; Research updates on diabetes

Jun 16, 2020

HCQ/ CQ failure; AZ/ Catalent’s deal; Sinovac’s CoronaVac and Lilly’s Olumiant trial results

Newsletter/Whitepaper